Brief: Zura Bio Launches Global Phase 2 Tibushield Study To Evaluate Tibulizumab In Adults With Hidradenitis Suppurativa
20/05/2025 12:07
May 20 (Reuters) - Zura Bio Ltd ZURA.O: ZURA BIO LAUNCHES GLOBAL PHASE 2 TIBUSHIELD STUDY TO EVALUATE TIBULIZUMAB IN ADULTS WITH HIDRADENITIS SUPPURATIVA ZURA BIO LTD - TOPLINE RESULTS EXPECTED IN Q3 2026 Source text: ID:nBwqfL1qa Further company coverage: ZURA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zura Bio
See all newsZura Bio Ltd reports results for the quarter ended June 30 - Earnings Summary
Zura Bio Q2 net loss widens as R&D expenses rise
Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zura Bio Expands Leadership Team With Appointment Of Muzammil Mustufa As Chief Business Officer